Do you continue daratumumab beyond 24 months in first line treatment of amyloidosis?

While Andromeda only goes to 24 mos, I usually go beyond that: especially in these scenerios

• patient has smoldering myeloma (instead of MGUS)
• high risk mutations: t(4:14). rarely do we see TP53
• Persistent MRD+. I do repeat BMs and MRD assessment at least first 2 years ( thankfully we have not had probl...